Angelica Gigas Dietary Supplements and Human Immune Cells

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-02-06

Study Completion Date

2026-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This human study will test the impact of dietary supplement vegicaps containing Korean Angelica root extract on 2 types of human immune cells: neutrophils that kill bacteria and other germs and natural killer (NK) cells that kill virus-infected cells and cancers. The investigators had done an earlier study with Korean Angelica supplement and discovered even a single dose of it increased blood neutrophils and NK cells within 24 h. In the new study, Korean Angelica capsules (Cogni.Q) will be compared head-to-head with dummy (placebo) capsules. This is to make sure the immune boosting actions are really from the Korean Angelica supplement.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

T Cells Response to SARS COV 2 Peptides

NCT04573348

Covid19 Corona Virus Infection

UNKNOWN

Understanding Adaptive Immune Response After COVID-19 Vaccination Boosters to Improve Vaccination Strategies in Vulnerable Groups.

NCT06300853

COVID-19

RECRUITING NA

Immune Cell Response to Stimuli

NCT00397280

Inflammation

RECRUITING

Effects of Systemically Administered Hydrocortisone on the Immune System in Healthy Volunteers

NCT01281995

Immunosuppression Healthy Healthy Subjects

COMPLETED

Humoral and Cellular Immune Response to COVID-19 Vaccines in Immunocompromised and Healthy Individuals

NCT04858607

Covid19 Immunosuppression

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Innate Immune Cells

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cogni.Q

800 mg per day (Two 200 mg capsules in the morning and two 200 mg capsules in the evening) for 21 days

Group Type EXPERIMENTAL

Cogni.Q

Intervention Type DIETARY_SUPPLEMENT

AGN

Placebo

Intervention Type OTHER

Placebo

Two capsules in the morning and two capsules in the evening for 21 days

Group Type PLACEBO_COMPARATOR

Cogni.Q

Intervention Type DIETARY_SUPPLEMENT

AGN

Placebo

Intervention Type OTHER

Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cogni.Q

AGN

Intervention Type DIETARY_SUPPLEMENT

Placebo

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects weighing between 110 to 240 pounds; their body mass index (BMI) should be in the range of 19 to 30
* Subjects having normal hepatic, renal function as assessed by history, physical and clinical chemistry analysis (CMP eGFR, see supporting document for normal reference ranges).
* Subjects with normal blood pressure (systolic below 120 mm Hg and diastolic below 80 mm Hg)

Exclusion Criteria

* Subjects positive for HIV, HBV and HCV (self-reported)
* Subjects taking any kind of prescription medications regularly or within 10 days of the study will be excluded. Therefore, subjects with diabetes, major cardiovascular diseases, cancer, severe hypertension, severe hepatic cirrhosis or cirrhosis of the liver, and kidney disease (self-reported) will be excluded.
* Subjects using tobacco products, nicotine patches and excessive alcohol
* Subjects taking dietary or herbal supplements that contain AGN (e.g. Cogni.Q, Decursinol-50, Ache Action, Fast-Acting Joint Formula, EstroG-100/Profemin) within 10 days of the study.
* Non-English-speaking subjects

Minimum Eligible Age

21 Years

Maximum Eligible Age

65 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes